Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

GSK Pulls Plug on Late-Stage Lung Cancer Trial

GSK Pulls Plug on Late-Stage Lung Cancer Trial | Lung Cancer Dispatch | Scoop.it

"GlaxoSmithKline has been forced to halt a Phase III trial assessing its MAGE-A3 cancer immunotherapeutic in patients with non-small cell lung cancer (NSCLC).


"High hopes for the experimental immunotherapy - designed to help patients stave off the return of the disease after treatment - came after it emerged that researchers would not be able to identify a subset of patients who may benefit from its therapy, hot on the heels of other disappointing data."


Editor's note: Immunotherapy drugs are meant to boost a patient's own immune system to fight cancer. We previously posted about the immunotherapy drug MAGE-A3. Even though it did not perform very well when tested in a clinical trial, researchers hoped to find a subset of patients who could benefit. However, it seems they could not.

Cancer Commons's insight:

PharmaTimes  |  Apr 2, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic Does Not Meet First Co-Primary Endpoints in MAGRIT, a Phase III Non-Small Cell Lung Cancer Clinical Trial

Investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic Does Not Meet First Co-Primary Endpoints in MAGRIT, a Phase III Non-Small Cell Lung Cancer Clinical Trial | Lung Cancer Dispatch | Scoop.it

"GlaxoSmithKline plc (LSE:GSK) today announced that analysis of the MAGRITi trial, a phase III trial of its MAGE-A3 cancer immunotherapeuticii in non-small cell lung cancer (NSCLC) patients, showed that the trial did not meet its first or second co-primary endpoint as it did not significantly extend disease-free survival (DFSiii) when compared to placebo in either the overall MAGE-A3 positive population (first co-primary endpoint) or in those MAGE-A3-positive patients who did not receive chemotherapy (second co-primary endpoint). GSK currently remains blinded to the overall trial data from the analysis of the first two co-primary endpoints to allow for the unbiased generation of a mathematical model to assess the third co-primary endpointiv."


Editor's Note: This story is about a drug that is meant to boost the patient's own immune system to fight lung cancer. The study has found no significant survival benefit of the drug, but the drug company hopes to find a sub-population of people with lung cancer for whom the drug will work. Learn more about immunotherapy and clinical trials.

Cancer Commons's insight:

GSK  |  Mar 20, 2014

more...
No comment yet.